# Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

> **NCT04578639** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Haukeland University Hospital** · enrollment: 214 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT04578639
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-02
- **Primary completion:** 2025-08-14
- **Final completion:** 2025-09-14
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578639, "Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04578639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*